Clopidogrel
Stroke Disorder
Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Shanghai CureGene Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619885CT.gov The Pharmacokinetics and Pharmacodynamics Study of CG-0255 Besylate and Plavix® in Healthy Participants | — | Recruiting | — | — | — |
NCT07237308CT.gov BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis | — | Not Yet Recruiting | — | — | — |
NCT07095790CT.gov Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke | — | Recruiting | — | — | — |
NCT06587347CT.gov Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke | — | Not Yet Recruiting | — | — | — |
NCT05902000CT.gov Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion | — | Unknown | — | — | — |
NCT05047172CT.gov Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | — | Active Not Recruiting | — | — | — |
NCT04733742CT.gov Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke | — | Completed | — | — | — |
NCT04948749CT.gov Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial | — | Recruiting | — | — | — |
NCT04491695CT.gov Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke | — | Unknown | — | — | — |
NCT04045665CT.gov Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | — | Recruiting | — | — | — |
Show 14 more trialsShow fewer
NCT04078737CT.gov Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II | — | Completed | — | — | — |
NCT03635749CT.gov Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis | — | Unknown | — | — | — |
NCT02975076CT.gov Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study | — | Unknown | — | — | — |
NCT02550717CT.gov Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN) | — | Completed | — | — | — |
NCT02506140CT.gov Platelet Reactivity in Acute Non-disabling Cerebrovascular Events | — | Completed | — | — | — |
NCT02398656CT.gov A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion | — | Completed | — | — | — |
NCT02446730CT.gov Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome | — | Unknown | — | — | — |
NCT02247128CT.gov Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation | — | Completed | — | — | — |
NCT01642134CT.gov Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI | — | Completed | — | — | — |
NCT01141153CT.gov Anticoagulation in Stent Intervention | — | Unknown | — | — | — |
NCT01661322CT.gov Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke | — | Terminated | — | — | — |
NCT00363753CT.gov Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack | — | Withdrawn | — | — | — |
NCT00238667CT.gov To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection | — | Completed | — | — | — |
NCT00153062CT.gov PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clopidogrel (this asset) | Shanghai CureGene Pharmaceutical Co., Ltd. | Approved | BB · 71 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Tirofiban | Weifang Medical University | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Clopidogrel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 81 |
| Transient Ischemic Attack | — | P4 | BBB · 77 |
| Peripheral Arterial Disease | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Clopidogrel in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/clopidogrel-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →